Iterum Therapeutics (ITRM) Expected to Announce Quarterly Earnings on Thursday

Iterum Therapeutics (NASDAQ:ITRM) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 13th. Analysts expect Iterum Therapeutics to post earnings of ($0.13) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 13, 2025 at 8:30 AM ET.

Iterum Therapeutics (NASDAQ:ITRM) last issued its earnings results on Tuesday, August 5th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.03).

Iterum Therapeutics Trading Up 0.7%

Shares of NASDAQ:ITRM opened at $0.62 on Thursday. The firm has a 50 day moving average of $0.69 and a 200-day moving average of $0.85. The stock has a market capitalization of $29.61 million, a PE ratio of -0.72 and a beta of 3.09. Iterum Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.02.

Hedge Funds Weigh In On Iterum Therapeutics

A hedge fund recently bought a new stake in Iterum Therapeutics stock. Jane Street Group LLC purchased a new stake in Iterum Therapeutics PLC (NASDAQ:ITRM) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 92,943 shares of the company’s stock, valued at approximately $92,000. Jane Street Group LLC owned 0.21% of Iterum Therapeutics as of its most recent filing with the Securities and Exchange Commission. 9.21% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently commented on ITRM. Weiss Ratings restated a “sell (d-)” rating on shares of Iterum Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Iterum Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 26th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $9.00.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.